Sign In
Buy TIL
$8.23
+0.120 (+1.48%)
At Close: Jun 03, 2026
Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a co
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
07:00am, Friday, 15'th May 2026
DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first q
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
07:00am, Friday, 27'th Mar 2026
Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current o
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
07:00am, Tuesday, 24'th Feb 2026
50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE N
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
06:56pm, Thursday, 12'th Feb 2026
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to conta
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
01:47pm, Tuesday, 03'rd Feb 2026
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL). Such investors are ad
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
10:00am, Thursday, 29'th Jan 2026
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to conta
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
01:20pm, Tuesday, 27'th Jan 2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL). Such investors are ad
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
10:00am, Thursday, 22'nd Jan 2026
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to conta
TIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & Korsinsky
03:03pm, Tuesday, 20'th Jan 2026
New York, New York--(Newsfile Corp. - January 20, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Instil Bio, Inc. ("Instil Bio, Inc.") (NASDAQ: TIL) concerning
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
01:33pm, Tuesday, 20'th Jan 2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL). Such investors are ad
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
10:00am, Thursday, 15'th Jan 2026
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to conta
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
04:02pm, Tuesday, 13'th Jan 2026
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL). Such investors are advis
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
10:16pm, Thursday, 08'th Jan 2026
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to conta
Instil Bio shares slide on discontinuation of lead clinical programs
04:11pm, Tuesday, 06'th Jan 2026
Instil Bio (NASDAQ:TIL) shares plummeted 46% to about $7 after the company announced its decision to discontinue development of its lead clinical assets AXN-2510 and AXN-27M and to terminate its partn
